Researchers have identified how a membrane molecule can hold a light-sensing channel in the eye closed, a laboratory finding that may guide future work on certain retinal disorders but is not yet a treatment.
The study published Sept. 3 in Nature Communications examined PIP2, a lipid present in cell membranes, and a channel in retinal rod cells known as a cyclic nucleotide-gated channel. A Weill Cornell Medicine summary said earlier work suggested PIP2 could inhibit the channel, which helps regulate rod cells' response to low light, but the binding mechanism had been unclear.
The team placed purified human channel proteins into model membrane structures with controlled PIP2 levels. Electrical and chemical tests showed inhibition even at concentrations estimated for rod-cell membranes. Cryogenic electron microscopy then located where PIP2 binds and showed that it stabilizes closed channel shapes, preventing opening.
Senior author Crina Nimigean said locating the binding site offers a possible target for future drugs affecting these channels. Some inherited channel defects can damage rod cells and cause vision loss, but the work was done in reconstructed membranes and structural models, not in patients. It did not demonstrate a drug, restore sight or prove how strongly the mechanism operates in living human eyes.
First author Taehyun Park said the team thinks the interaction is part of the natural tuning of light sensitivity. Researchers are next studying lipids that activate, rather than inhibit, the channels.
The study was supported by the National Institutes of Health. It does not report a Finger Lakes-specific clinical finding.
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to news@fingerlakes1.com.